Skip to main content
Abbisko Cayman Limited logo

Abbisko Cayman Limited — Investor Relations & Filings

Ticker · 2256 ISIN · KYG0028A1085 LEI · 655600UAX2YV03PRXN31 HKEX Manufacturing
Open in API
Filings indexed 402 across all filing types
Latest filing 2026-03-30 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 2256

About Abbisko Cayman Limited

http://www.abbisko.com

Abbisko Cayman Limited is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative and differentiated small molecule therapies. The company leverages a robust in-house R&D engine and a multi-dimensional discovery platform to advance a rich pipeline focused primarily on oncology, encompassing both precision-oncology and immuno-oncology candidates. Key product candidates include pimicotinib, which has shown positive topline results for the treatment of tenosynovial giant cell tumor (TGCT). Abbisko aims to develop novel treatments that address critical unmet medical needs for patients globally.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - FGFR2/3 INHIBITOR ABSK061 RECEIVES FDA IND CLEARANCE FOR ACHONDROPLASIA IN CHILDREN
Regulatory Filings Classification · 1% confidence The document is a voluntary corporate announcement/press release by Abbisko Cayman Limited about FDA IND clearance for a drug candidate. It contains no financial results, board changes, share transactions, or formal report attachments – it’s not an earnings release, annual or interim report, dividend notice, or proxy statement. It does not fit any specialized category, so it defaults to the general regulatory announcement category.
2026-03-30 English
VOLUNTARY ANNOUNCEMENT - FGFR2/3 INHIBITOR ABSK061 GRANTED ORPHAN DRUG DESIGNATION BY FDA FOR ACHONDROPLASIA
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement issued by Abbisko Cayman Limited regarding the FDA granting Orphan Drug Designation to its drug candidate ABSK061. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement. As it is a general regulatory announcement regarding company business developments, it falls under the RNS (Regulatory Filings) category.
2026-03-19 English
VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS' IRPAGRATINIB COMBINED WITH TARGETED-IMMUNOTHERAPY COMPLETES FIRST PATIENT DOSING IN PHASE II TRIAL FOR FIRST-LINE TREATMENT OF ADVANCED HCC
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement issued by Abbisko Cayman Limited regarding the clinical trial progress of its drug candidate, irpagratinib. It details the completion of first patient dosing in a Phase II trial. This type of corporate update, which does not fit into specific financial reporting categories like 10-K or IR, and is not a report publication announcement (RPA) as it contains the substantive news itself, is best classified as a general regulatory filing (RNS) under the provided schema.
2026-03-16 English
VOLUNTARY ANNOUNCEMENT - FDA GRANTED RARE PEDIATRIC DISEASE DESIGNATION FOR FGFR2/3 INHIBITOR ABSK061
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement issued by Abbisko Cayman Limited regarding the FDA granting Rare Pediatric Disease designation to one of its drug candidates (ABSK061). It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement. As it is a general regulatory announcement regarding company operations and drug development status, it falls under the 'Regulatory Filings' (RNS) category.
2026-03-11 English
VOLUNTARY ANNOUNCEMENT - THE LANCET PUBLISHES GLOBAL PHASE 3 MANEUVER STUDY RESULTS OF PIMICOTINIB
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement issued by Abbisko Cayman Limited regarding the publication of clinical trial results (Phase 3 MANEUVER study) in the medical journal The Lancet. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a mandatory regulatory filing for a specific corporate action like a dividend or board change. As it is a general corporate announcement regarding business/clinical developments, it falls under the 'Regulatory Filings' (RNS) category as the fallback for miscellaneous announcements.
2026-03-09 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2026
Regulatory Filings Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies in Hong Kong to report monthly movements in securities, share capital, and treasury shares. It does not fit into specific categories like 10-K, Earnings Release, or M&A. As it is a recurring regulatory filing mandated by the Exchange Listing Rules, it is best classified under the 'Regulatory Filings' (RNS) category.
2026-03-05 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.